Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Notice to Readers Bacterial Sepsis Associated with Receipt of Albumin

The Food and Drug Administration (FDA) has designated as Class I (defined by FDA as a strong likelihood that a product will cause serious adverse health consequences or death) a recall of Centeon Albumin, 25% (Human), U.S.P., Albuminar{Registered}-25 (manufactured by Centeon L.L.C., King of Prussia, Pennsylvania), lot number P61205, because of Enterobacter cloacae sepsis associated with receipt of product from this lot. Contamination of the product may have been due to cracks in the vials during manufacture. Cultures of unopened product grew Stenotrophomonas multophilia and enterococci in addition to E. cloacae. Ten other lots (P18607, L8212, M60902, M54512, L58211, M61403, M63204, M54912, P61805, and P62906) of Centeon Albuminar{Registered}-25 and Albuminar{Registered}-5 (albumin, 5% {human}, U.S.P.) also have been recalled as a precaution because of the potential for contamination due to similar manufacturing problems.

Hospitals, dialysis centers, and other users should discontinue use of these lots of Centeon Albuminar{Registered} and quarantine all vials belonging to these lots. Other lots should not be used if the vials are visibly cracked or the contents are visibly turbid. Health-care professionals should report any episode of infection associated with Centeon Albuminar{Registered} to CDC's Hospital Infections Program, National Center for Infectious Diseases (telephone {404} 639-6413; fax {404} 639-6459), and to FDA's MedWatch Program (telephone {800} 332-1088; fax {800} 332-0178).

Centeon also is voluntarily recalling a single lot (P72304) of Monoclate-P{Registered} Factor VIII used to treat hemophilia; no adverse events have been reported in association with Monoclate-P {Registered}. The investigation by FDA and Centeon is ongoing, and additional information is available from FDA's Center for Biologics Evaluation and Research, telephone (301) 827-2000 or (800) 835-4709.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Road Atlanta, GA 30329-4027, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #